Analysts: Honeywell Has Healthy Growth Plans and 4 More Research Notes to Read Now

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Honeywell International Inc. (NYSE:HON): The company revealed its long-term growth plans, which causes Oppenheimer to think that the stock’s multiple has the potential to expand. The firm reiterates its Outperform rating on the stock.

The stock market is roaring back in 2013. Click here now to discover winning stocks!

HON

Texas Instruments Inc. (NYSE:TXN): Susquehanna thinks that Texas Instruments’ current valuation is still rich after its mid-quarter update. The company decided to increase the midpoint of its revenues and earnings guidance, but Susquehanna is convinced that the majority of the upside comes from wireless which the company is winding down. The firm gives the stock a Neutral rating and a price target of $30.

The stock market is roaring back in 2013. Click here now to discover winning stocks!

TXN

Acquity Group (AMEX:AQ): Acquity Group announced its intention to explore strategic options for its two joint ventures, which causes William Blair to believe that the decision is positive. The firm thinks that the ventures harm Acquity’s domestic operations and haven’t gained as much traction as previously expected. The firm recommends purchasing Acuity’s shares at current levels.

The stock market is roaring back in 2013. Click here now to discover winning stocks!

AQ

Westport Innovations Inc. (NASDAQ:WPRT): Jefferies predicts that Westport will have a “choppy” 1H13, but the firm also expects for the company to have several positive catalysts over the next 12-18 months. It believes that the next few months has the potential to provide a good entry point in the stock.

The stock market is roaring back in 2013. Click here now to discover winning stocks!

WPRT

Celldex Therapeutics, Inc. (NASDAQ:CLDX): Jefferies decided to raise its price target on Celldex due to the firm’s belief that the company’s pipeline outlook appeared encouraging. The firm believes that Celldex is a compelling biotech player possessing a number of shots on goal, and it reiterates its Buy rating on the stock.

The stock market is roaring back in 2013. Click here now to discover winning stocks!

CLDX

Investing Insights: Where Will Qualcomm Go Next?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business